Tracking the History of Tucatinib for Breast Cancer Treatment at SABCS
Throughout the years, SABCS has shown how tucatinib has progressed into a potential frontline therapy for HER2-positive breast cancer.
Progress Against Cancer
Throughout the years, SABCS has shown how tucatinib has progressed into a potential frontline therapy for HER2-positive breast cancer.
New insights into the neurologic and physiologic impact of chronic stress on ovarian cancer were presented at two recent AACR conferences.
In November, the AACR’s journal editors highlighted studies on sucralose limiting immunotherapy, benefits of caloric restriction, and more.
Shawn Lee, MD, PhD, an AACR-St. Baldrick’s Foundation Grantee, is working to personalize therapies for children with acute lymphoblastic leukemia.
More people with breast cancer can forgo radiation after surgery, and a treatment combination helps control esophageal cancer.
Promising early-phase clinical trial data were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
Researchers are exploring innovative early cancer detection strategies involving tiny cancer hunters, the voice, electronic noses, and more.
Adding chemotherapy to targeted therapy improves outcomes for people with advanced EGFR-positive non-small cell lung cancer.
Since 1993, the American Association for Cancer Research (AACR) has invested more than $542 million in grants to sustain the pipeline of cancer researchers and accelerate breakthroughs for patients. The second annual AACR Grantee...
A look at recent research on determining breast cancer risk, the impact of lifestyle changes on cancer risk, and why screening is important.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More